Early Bisphosphonate Treatment Benefits Infants With Osteogenesis Imperfecta

Description: Early cyclical neridronate treatment has positive effects on growth and fracture rate in infants with severe osteogenesis imperfecta (OI), according to researchers. In a study published in the August issue of the Journal of Pediatrics, Italian researchers prospectively assessed the efficacy of bisphosphonate treatment in infants with severe OI. Included in the study were 10 children with OI type III. Of these, five (group A) started treatment (2 mg/kg neridronate given intravenously for 2 consecutive days, every 3 months) at a mean age of 37 days and five (group B) started treatment after 6 months (mean age of 220 days). Ten untreated children matched for sex, age, and clinical severity of OI, served as an historical control group (group C). [p 174, para 2,3 and p 175, col 1, para 1,2,3]